Calcium-based phosphate binders are used to control hyperphosphatemia; however, they
promote hypercalcemia and may accelerate aortic calcification. Here we compared the effect …

The alternative phosphate binder calcium acetate/magnesium carbonate (CaMg) effectively
reduces hyperphosphatemia, the most important inducer of vascular calcification, in chronic …

Background. Hyperphosphataemia is a risk factor for arterial calcification contributing to the
high cardiovascular mortality in patients with chronic kidney disease. Calcium-based …

Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term
experimental uremia. Background In chronic renal failure (CRF), hyperphosphatemia and an …

The role of hyperphosphatemia in the pathogenesis of secondary hyperparathyroidism,
cardiovascular disease, and progression of renal failure is widely known. Here we studied …

Chronic renal failure (CRF) is associated with the development of secondary
hyperparathyroidism and vascular calcifications. We evaluated the efficacy of PA21, a new …

Pathogenesis of vascular calcification in chronic kidney disease. Background
Hyperphosphatemia and hypercalcemia are independent risk factors for higher incidence of …

The control of serum phosphorus (P) and calcium-phosphate (Ca× P) product is critical to
the prevention of ectopic calcification in chronic renal failure (CRF). Whereas calcium (Ca) …

Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic
renal failure rats. Background Hyperphosphatemia is associated with severe complications …

Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-
day oral administration. Background Lanthanum (La) carbonate has recently been proposed …